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Background: Tumor spreading is the major threat for cancer patients. The recently published anti-cancer drug
salinomycin raised hope for an improved treatment by targeting therapy-refractory cancer stem cells. However, an
unambiguous role of salinomycin against cancer cell migration and metastasis formation remains elusive.
Findings: We report that salinomycin effectively inhibits cancer cell migration in a variety of cancer types as
determined by Boyden chamber assays. Additionally, cells were treated with doxorubicin at a concentration causing a
comparable low cytotoxicity, emphasizing the anti-migratory potential of salinomycin. Moreover, single-cell tracking
by time-lapse microscopy demonstrated a remarkable effect of salinomycin on breast cancer cell motility. Ultimately,
salinomycin treatment significantly reduced the metastatic tumor burden in a syngenic mouse tumor model.
Conclusions: Our findings clearly show that salinomycin can strongly inhibit cancer cell migration independent of the
induction of cell death. We furthermore demonstrate for the first time that salinomycin treatment reduces metastasis
formation in vivo, strengthening its role as promising anti-cancer therapeutic.
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Distant metastases are the major cause of death in pa-
tients suffering from cancer. In spite of this, there is a lack
of effective treatments for patients with metastatic disease.
The discovery and development of novel drugs which can
potently inhibit cancer cell migration and hence prevent
metastasis formation are therefore of great interest in
order to prolong the survival of patients. Gupta et al. have
recently found salinomycin to be a selective inhibitor of
cancer stem cells (CSC) obtained from immortalized
transformed HMLER cells by a stable E-cadherin knock-
down. Salinomycin reduced the proportion of CSC more
than 100-fold as compared to paclitaxel, a commonly used
chemotherapeutic breast cancer drug [1]. Subsequent
studies in a variety of different cancer types including
breast, blood, lung, pancreas and colon have revealed
diverse mechanisms of salinomycin action against CSC
resulting in an inhibition of proliferation or an induction
of apoptosis and cell death [2]. Very recently, some re-
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stated.migration in different cancer types [3-8]. However, when
looking at these studies in more detail, some of them raise
concerns regarding the salinomycin concentration used
for the migration experiments. Moreover, the ultimate ef-
fect of salinomycin treatment on metastasis formation
in vivo had yet to be elucidated.
In this study, we wanted to investigate whether salino-
mycin is able to inhibit migration in a variety of cancer
types. In order to rule out that the inhibition of cell mo-
tility is due to unspecific cytotoxic effects, we focused on
the use of salinomycin concentrations which only cause
minor cytotoxicity. Finally, a syngenic mouse model for
metastasis was utilized to prove the efficacy of salinomy-
cin against tumor dissemination.
Salinomycin treatment effectively hampers migration in
cancer cells
To examine whether salinomycin has a strong anti-
migratory effect on cells derived from several different
cancer types, we performed Boyden chamber assays in
which we treated the human breast cancer cell line
MDA-MB-436, the murine lung cancer cell line Lewis
lung carcinoma (LLC) and the murine breast cancer cell
line 4T1-luc (i.e. 4T1 cells stably expressing fireflytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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nomycin. All materials and methods are described in detail
in Additional file 1: Supplementary materials and methods.
Thereby, the concentrations of salinoymcin and doxorubi-
cin were chosen to cause a low and comparable cytotoxi-
city (Figure 1B and Figure 1D). In all salinomycin-treated
cells migration was significantly reduced as compared to
mock- or doxorubicin-treated cells (Figure 1A), indicating
that the inhibitory effect of salinomycin on migration is
not due to unspecific cytotoxicity. Apart from the breast
and lung cancer cell lines, we analyzed the migratory cap-
ability of the primary low passaged colon cancer cell lines
COGA2 and COGA10, which were derived from colon
cancer patients as previously described by Vecsey-Semjen
et al. [9]. Interestingly, salinomycin treatment significantly
inhibited the migration of these primary colon cancer cells
as compared to mock treatment (Figure 1C).
Time-lapse microscopy reveals an inhibition of the
motility of MDA-MB-436 cells upon salinomycin treatment
Moreover, we analyzed the effect of salinomycin on the
cell motility of MDA-MB-436 cells in more detail using
time-lapse microscopy. In a scratch assay, mock-A
C
Figure 1 Salinomycin treatment effectively hampers migration in can
during treatment. MDA-MB-436, LLC and 4T1-luc cells were treated for 18 h with
salinomycin, respectively. The number of migrated mock-treated (control) cells w
viability upon doxorubicin or salinomycin treatment. MDA-MB-436, LLC and 4T1
doxorubicin or salinomycin. Cell viability was determined by a CellTiter Glo assay
migration assays of primary colon cancer cells. COGA2 and COGA10 cells were t
salinomycin (2.5 μM and 5 μM, respectively). The number of migrated mock-trea
compared to control; *p < 0.05). D) Cell viability upon doxorubicin or salinomyci
mentioned concentrations of doxorubicin or salinomycin. Cell viability was deter(control) as well as doxorubicin-treated cells migrated
into the scratch, whereas salinomycin treatment pre-
vented wound closure (Figure 2A and Supplement
videosa). Importantly, concentrations of salinomycin and
doxorubicin were chosen to cause a comparable low
cytotoxicity of less than 10% (Additional file 2: Figure
S1). Subsequent analysis of individually tracked cells re-
vealed that the accumulated distance (Figure 2B) and
the velocity (Figure 2C) of salinomycin-treated cells
were significantly reduced as compared to mock- or
doxorubicin-treated cells. This effect became even more
evident when looking at the moving direction of the
cells treated with salinomycin (Figure 2D). In addition,
we performed a scratch assay with the human breast
cancer cell line MDA-MB-231 to further demonstrate
the potent inhibitory effect of salinomycin on cancer
cell motility (Additional file 3: Figure S2). Moreover, the
salinomycin-induced changes on the cell morphology
and cytoskeleton of MDA-MB-436 were analyzed by
immunofluorescence microscopy (Additional file 4:
Figure S3). These findings clearly demonstrate the
strong anti-migratory effects of salinomycin on various
cancer cells in vitro.B
D
cer cells. A) Boyden chamber migration assays of different cancer cell lines
10 μM, 0.5 μM and 0.5 μM doxorubicin or 0.05 μM, 0.5 μM and 0.05 μM
as set to 100%. (Student’s t-test, two-tailed, *p < 0.05; **p < 0.01). B) Cell
-luc cells were treated for 18 h with afore mentioned concentrations of
and normalized to mock-treated control cells. C) Boyden chamber
reated for 18 h with either doxorubicin (10 μM and 10 μM, respectively) or
ted (control) cells was set to 100%. (Student’s t-test, two-tailed, salinomycin
n treatment. COGA2 and COGA10 cells were treated for 18 h with afore
mined by a CellTiter Glo assay and normalized to mock-treated control cells.
Figure 2 Time-lapse microscopy reveals an inhibition of the motility of MDA-MB-436 cells upon salinomycin treatment. A) Wound
healing assay of MDA-MB-436 cells. Cells were treated either with mock (control), doxorubicin (0.05 μM) or salinomycin (0.05 μM) and monitored for 72 h.
The same cells as for the wound healing assay were used for time-lapse microscopy. Manually tracked cells were analyzed for B) the accumulated distance,
C) the velocity and D) the direction of movement. (Student’s t-test, two-tailed, ****p < 0.0001).
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in a syngenic intravenous mouse tumor model
Based on these observations, we raised the question
whether salinomycin is able to prevent metastasis in vivo.
Hence, we injected 4T1-luc cells into the tail vein ofBALB/c mice and treated them with salinomycin at indi-
cated time points. Primary tumor formation in the lungs
was monitored in vivo using bioluminescence imaging as
described previously [10]. Interestingly, there was no sig-
nificant effect of salinomycin treatment on primary tumor
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images of the tumor-bearing mice (Figure 3B) and analysis
of the respective resected 4T1-luc tumor-bearing lungs
(Figure 3C) of mock- and salinomycin-treated mice fur-
ther confirmed that there was no major effect on primary
tumor growth in the lungs. However, when analyzing the
metastatic tumor burden in other organs using an ex vivo
luciferase assay metastases were significantly reducedA
C
E
Figure 3 Metastasis formation is reduced by salinomycin treatment in
4T1-luc tumors in the lung. 1×105 4T1-luc cells were intravenously injected
with mock (control) or 5 mg/kg salinomycin on day 0, 3, 6 and 9. Tumor g
bioluminescence imaging. B) Live imaging of 4T1-luc tumors in mouse lun
and ventrodorsal (lower panel) position and presented for day 13. Signal in
imaging of 4T1-luc tumor-bearing lungs. Mice were euthanized on day 13
mice were imaged. Signal intensities are displayed as photons/second/cm2
4T1-luc tumor-bearing mice. D) Brain, E) spleen and F) kidneys were analyz
one-tailed; *p < 0.05; **p < 0.01).upon salinomycin treatment in brain (Figure 3D), spleen
(Figure 3E) and kidneys (Figure 3F).
In summary, salinomycin had considerable inhibitory ef-
fects on cell migration in several different cancer cell lines
including MDA-MB-436 (breast), MDA-MB-231 (breast),
4T1-luc (breast), LLC (lung), COGA2 (colon) and
COGA10 (colon) when applied at low dose. Selective tar-
geting of CSC and induction of oxidative stress have beenB
D
F
a syngenic intravenous mouse tumor model. A) Tumor growth of
into 10 female BALB/c mice per group. Animals were treated either
rowth was monitored for 13 days at indicated time points using
gs. Bioluminescence images were taken in dorsoventral (upper panel)
tensities are displayed as photons/second/cm2 (scale bar). C) Ex vivo
and the resected lungs of mock- (control) and salinomycin-treated
. (Student’s t-test, two-tailed; ns = not significant). Metastases in
ed for metastases using an ex vivo luciferase assay. (Student’s t-test,
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[4,6]. Verdoodt et al. have recently demonstrated that sali-
nomycin induces autophagy in colon and breast cancer
cells [11], which might also hinder cells to migrate as
autophagy has been shown to inhibit migration in hepa-
titis B virus-associated hepatocellular carcinoma and in
HeLa cells [12,13]. It is furthermore well established that
salinomycin treatment leads indirectly to an influx of
calcium ions into the cytoplasm most likely via the
potassium/calcium antiporter [14,15]. Gradients of cal-
cium are crucial for polarized cell migration in mesenchy-
mal cells. In the leading edge protrusion transient calcium
flickers are induced by chemokines and regulate direc-
tional decision making [16]. Similarly, it was speculated
that detachment of the trailing edge is also calcium
dependent [17]. Recently, Witze et al. [18] demonstrated
that Wnt5a induces ER mobilization to the trailing edge
in migrating cells controlling calcium signaling via ER
tubules, finally resulting in the activation of calpain pro-
teases and substrate detachment. The collapse of the fine
tuned calcium balance at both cellular edges by additional
influx of calcium induced by salinomycin might lead to a
breakdown of the calcium gradients hindering cells to exe-
cute directed movements.
In some of the previous studies in which they treated
cells with salinomycin for migration experiments [4,7,8],
relatively high salinomycin concentrations were used so
that in our view the inhibitory effect on cell motility can-
not be exclusively attributed to anti-migratory effects of
salinomycin but rather to unspecific cytotoxicity. Here, we
compared salinomycin- with doxorubicin-treated cells at
concentrations resulting in approximately 85 – 90% viable
cells. Since salinomycin treatment significantly reduced
the migratory capacity of the breast and lung cancer cell
lines to 50 – 55% in contrast to doxorubicin treatment,
we conclude that salinomycin is able to inhibit cancer cell
migration at low-toxic doses, independent of the induced
cytotoxicity. In case of the migratory potential of the pri-
mary colon cancer cell lines, salinomycin treatment was
not significantly superior to doxorubicin treatment due to
higher standard deviations. However, in COGA2 cells
treatment with non-toxic concentrations of salinomycin
(cell viability of approximately 100%) reduced the number
of migrated cells to 20 – 25%. The salinomycin concentra-
tion used for COGA10 cells (cell viability of approximately
75%) could at least reduce the number of migrated cells to
40 – 45%, albeit cytotoxic effects cannot be completely
excluded in this setting. Exemplarily, we performed time-
lapse microscopy of MDA-MB-436 cells to directly moni-
tor the immediate effects of salinomycin on cell motility,
i.e. the distance, the velocity and the direction of migrating
cells, on a single-cell level. The videos taken from these
experiments further underline the quantitative analyses of
the cell motility. Hence, we showed, to our knowledge forthe first time, that salinomycin inhibits migration of breast
cancer cells and primary colon cancer cells independent
of the induction of cell death. Consequently, we sought to
explore the efficacy of salinomycin on tumor dissemi-
nation in vivo. Gupta et al. pre-treated 4T1 cells with
salinomycin before they injected them intravenously into
mice. After three weeks they obtained a smaller tumor
burden upon salinomycin treatment in the lungs as deter-
mined by the lung tumor surface [1]. In this study, we
analyzed for the first time metastasis formation of intra-
venously injected firefly luciferase expressing 4T1-luc cells
which were not pre-treated with salinomycin. The
rationale behind this was to monitor the primary tumor
formation in the lungs via bioluminescence imaging as
well as to detect metastases in other organs via an ex vivo
luciferase assay. Of note, metastasis formation in brain,
spleen and kidneys from primary 4T1-luc tumors in the
lungs was considerably reduced by salinomycin treatment,
even though the growth of the primary lesion was not sig-
nificantly hampered. Thus, our in vitro and in vivo results
clearly demonstrate that salinomycin - initially a cancer
stem cell-specific drug – inhibits the migration of various
cancer cells and prevents tumor dissemination in mice.
These findings raise hope for improved treatment options
for cancer patients in the future.
Endnote
aSupplement videos of the wound healing assay of
MDA-MB-436 cells treated either with mock (control),
doxorubicin or salinomycin are available on our homepage:
http://www.cup.lmu.de/pb/aks/ewagner/projects.html.
Additional files
Additional file 1: Supplementary materials and methods.
Additional file 2: Figure S1. Cell viability upon doxorubicin or
salinomycin treatment. MDA-MB-436 cells were treated for 72 h with
0.05 μM doxorubicin or 0.05 μM salinomycin. Cell viability was determined
by a CellTiter Glo assay and normalized to mock-treated control cells.
Additional file 3: Figure S2. Wound healing assay of MDA-MB-231
cells. Cells were treated either with mock (control), doxorubicin (0.05 μM)
or salinomycin (0.10 μM) and monitored for 48 h using the IncuCyte
ZOOM 40008 instrument (ESSEN BioScience) (upper panel). The relative
wound density was analyzed using the IncuCyte ZOOM 2013A software
(lower panel). (Values are stated as mean ± SEM, student’s t-test,
two-tailed, ****p < 0.0001).
Additional file 4: Figure S3. Immunofluorescence microscopy of
salinomycin-treated MDA-MB-436 cells. Cells were grown to a confluency
of 80 – 90% and a scratch was placed. Subsequently, cells were treated
with 500 nM salinomycin for 24 h and stained with anti-vinculin antibody
(green), rhodamine phalloidin (F-actin, red) and DAPI (nuclei, blue).
Representative pictures are shown.
Abbreviation
CSC: Cancer stem cells.
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